September 24 - 27, 2017
Disney’s Boardwalk Inn
Orlando, Florida, USA
Abstract submission deadline: Tuesday, July 11
Advance registration deadline: Monday, August 14
Conference CochairsCory Abate-Shen, Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center, New York, New YorkKevin M. Haigis, Beth Israel Deaconess Medical Center, Boston, MassachusettsKaterina A. Politi, Yale Cancer Center, New Haven, ConnecticutJulien Sage, Stanford University School of Medicine, Stanford, California
Genetically engineered mouse (GEM) models are a mainstay for basic and translational cancer research. A veritable explosion of GEM models in recent years has been fueled by technological advances that have enabled the rapid generation of models of increasing complexity and relevance for human cancer. These next-generation GEM models have, in turn, provided key insights into all aspects of cancer biology, including elucidating the actions of oncogenes and tumor suppressor genes, understanding metastatic progression, uncovering the roles of the tumor microenvironment and immune system, identifying cancer cells-of-origin, and elucidating new therapeutic approaches and mechanisms of drug resistance. Analyses of GEM models have been augmented by their integration with complementary models of human cancer, such as organoid and patient-derived xenograft models. This meeting will highlight recent advances in modeling cancer using mouse models, focusing on their impact for advancing our understanding of cancer biology and treatment.